Pharma Industry News Watch
Global and Indian pharma-industry updates covering company moves, pipeline and clinical development, approvals, regulation, manufacturing, supply, commercial strategy and market access.
Dapagliflozin - Five Years since CKD Approval: Revisiting 5 Milestones in CKD Care - Medical Dialogues
Dapagliflozin - Five Years since CKD Approval: Revisiting 5 Milestones in CKD Care Medical Dialogues…
FDA Approves First Treatment for Rare MCT8 Deficiency, Allan-Herndon-Dudley Syndrome - Medical Dialogues
FDA Approves First Treatment for Rare MCT8 Deficiency, Allan-Herndon-Dudley Syndrome Medical Dialogues…
Aurobindo’s arm, Acrotech Biopharma, launches Adquey in US - BusinessLine
Aurobindo’s arm, Acrotech Biopharma, launches Adquey in US BusinessLine…
Regeneron weight-loss drug halves muscle loss in combination with Novo's semaglutide in trial - Reuters
Regeneron weight-loss drug halves muscle loss in combination with Novo's semaglutide in trial Reuters…
Liquidia slumps after US court rules for United Therapeutics in patent fight - Reuters
Liquidia slumps after US court rules for United Therapeutics in patent fight Reuters…
HHS announces new efforts to speed up, expand clinical trials with AI - STAT
HHS announces new efforts to speed up, expand clinical trials with AI STAT…
Pharma deals and data heat the weight-loss-drug market - Chemical & Engineering News
Pharma deals and data heat the weight-loss-drug market Chemical & Engineering News…
Bitter pills: on Court’s intervention, drug pricing - The Hindu
Bitter pills: on Court’s intervention, drug pricing The Hindu…
Pharma dept to offer gap funding for early-stage novel drug discovery - Business Standard
Pharma dept to offer gap funding for early-stage novel drug discovery Business Standard…
AbbVie’s eczema drug shows benefit in Phase 2; BioMarin lays off 117 - Endpoints News
AbbVie’s eczema drug shows benefit in Phase 2; BioMarin lays off 117 Endpoints News…
Hansoh’s Tagrisso rival loses EU approval after AstraZeneca legal challenge - Fierce Pharma
Hansoh’s Tagrisso rival loses EU approval after AstraZeneca legal challenge Fierce Pharma…
Varda raises $250 million at $1.6 billion valuation to scale orbital drug manufacturing - Reuters
Varda raises $250 million at $1.6 billion valuation to scale orbital drug manufacturing Reuters…
Novo’s weight-loss deal highlights its weakness and the seller’s strengths - Financial Times
Novo’s weight-loss deal highlights its weakness and the seller’s strengths Financial Times…
NorthStar locks down $185M as radiopharmaceutical isotope, CDMO expansion plans advance - Fierce Pharma
NorthStar locks down $185M as radiopharmaceutical isotope, CDMO expansion plans advance Fierce Pharma…
BioNTech to close German manufacturing plants after failing to find buyers - BioSpace
BioNTech to close German manufacturing plants after failing to find buyers BioSpace…
Vytalyou raises ₹9 crore pre-series A funding - ET Entrepreneur
Vytalyou raises ₹9 crore pre-series A funding ET Entrepreneur…
Drug patents in India: How they work and when govt can override them - Business Standard
Drug patents in India: How they work and when govt can override them Business Standard…
Ontario Contributes $1.7 Million Investment to Advance Life Sciences Innovation at Piramal Pharma's Aurora Facility - Business Standard
Ontario Contributes $1.7 Million Investment to Advance Life Sciences Innovation at Piramal Pharma's Aurora Facility Business Standard…
Roche, Zealand see phase 2 amylin weight loss peak at mid-dose, start pivotal program - Fierce Biotech
Roche, Zealand see phase 2 amylin weight loss peak at mid-dose, start pivotal program Fierce Biotech…
Lilly sets up next-gen obesity battle with full phase 3 retatrutide data - Fierce Biotech
Lilly sets up next-gen obesity battle with full phase 3 retatrutide data Fierce Biotech…
Apollo Hospitals, Yatharth, others fall up to 6% on SC's 'corporate hospitals don't spare anyone' remark - Moneycontrol.com
Apollo Hospitals, Yatharth, others fall up to 6% on SC's 'corporate hospitals don't spare anyone' remark Moneycontrol.com…
Anupam Rasayan completes acquisition of 48.2% stake in Bliss GVS Pharma - ET Manufacturing
Anupam Rasayan completes acquisition of 48.2% stake in Bliss GVS Pharma ET Manufacturing…
Clinical Research - Department of Pharmaceuticals | Government of India
Clinical Research Department of Pharmaceuticals | Government of India…
Canadian $5M accelerated clinical trial program cuts start-up to 45 days - Fierce Biotech
Canadian $5M accelerated clinical trial program cuts start-up to 45 days Fierce Biotech…
Pharma Pricing Under Siege: Key Interventions of the Month - India Pharma Outlook
Pharma Pricing Under Siege: Key Interventions of the Month India Pharma Outlook…
Anupam Rasayan takes control of Bliss GVS in ₹1,750 crore bet on pharma scale-up - Indiatimes
Anupam Rasayan takes control of Bliss GVS in ₹1,750 crore bet on pharma scale-up Indiatimes…
Quotient Sciences and Acesion Pharma Partner to Accelerate Formulation Development for Atrial Fibrillation Programs - Drug Development and Delivery
Quotient Sciences and Acesion Pharma Partner to Accelerate Formulation Development for Atrial Fibrillation Programs Drug Development and Delivery…
Fake Mounjaro to unapproved retatrutide: Inside India's booming weight-loss drug black market - Livemint
Fake Mounjaro to unapproved retatrutide: Inside India's booming weight-loss drug black market Livemint…
Summit snags $2B investment from AstraZeneca, clearing financial overhang - BioSpace
Summit snags $2B investment from AstraZeneca, clearing financial overhang BioSpace…
Surat-based Anupam Rasayan completes ₹1,750-cr acquisition of 48.2% in Bliss GVS Pharma - BusinessLine
Surat-based Anupam Rasayan completes ₹1,750-cr acquisition of 48.2% in Bliss GVS Pharma BusinessLine…
Rare diseases can be treated with tailored gene therapy but India’s regulatory system must evolve - Livemint
Rare diseases can be treated with tailored gene therapy but India’s regulatory system must evolve Livemint…
Kodiak’s stock rallies on Phase III wAMD success - Clinical Trials Arena
Kodiak’s stock rallies on Phase III wAMD success Clinical Trials Arena…
Novo buys rights to Chinese weight-loss pill in $2.6bn deal - Financial Times
Novo buys rights to Chinese weight-loss pill in $2.6bn deal Financial Times…
Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand Hengrui - Fierce Biotech
Novo agrees $2.6B deal for preclinical GLP-1/GIP drug from in-demand Hengrui Fierce Biotech…
Novo Buys Rights to Early Obesity Pill in $2.6 Billion Deal - Bloomberg.com
Novo Buys Rights to Early Obesity Pill in $2.6 Billion Deal Bloomberg.com…
FDA Investigation Leads to Charges Against Two Indian Nationals Involved in Transnational Counterfeit Drug Distribution Scheme - fda.gov
FDA Investigation Leads to Charges Against Two Indian Nationals Involved in Transnational Counterfeit Drug Distribution Scheme fda.gov…
AstraZeneca files US FDA application for HUTCHMED lung cancer drug combination - BusinessLine
AstraZeneca files US FDA application for HUTCHMED lung cancer drug combination BusinessLine…
Natco Pharma raises eGenesis investment to $16.70 million - BusinessLine
Natco Pharma raises eGenesis investment to $16.70 million BusinessLine…
Sayre Therapeutics Financials 2026 – Revenue, P&L & Cash Flow - Inc42
Sayre Therapeutics Financials 2026 – Revenue, P&L & Cash Flow Inc42…
Micro/RMM In-Depth Focus - European Pharmaceutical Review
Micro/RMM In-Depth Focus European Pharmaceutical Review…
Kodiak Sciences’ stock soars 166% after 2 assets match Eylea in Phase 3 trial - BioSpace
Kodiak Sciences’ stock soars 166% after 2 assets match Eylea in Phase 3 trial BioSpace…
Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitor - BioSpace
Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitor BioSpace…
Mirum posts phase 3 hepatitis win for ‘commercially differentiated’ challenger to Gilead, Vir - Fierce Biotech
Mirum posts phase 3 hepatitis win for ‘commercially differentiated’ challenger to Gilead, Vir Fierce Biotech…
Tolerance continues thymus-focused deals with $560M pact for Tanabe's clinical-stage IL-33 drug - Fierce Biotech
Tolerance continues thymus-focused deals with $560M pact for Tanabe's clinical-stage IL-33 drug Fierce Biotech…
Swiss groups seek reforms as clinical trial numbers fall - The Pharma Letter
Swiss groups seek reforms as clinical trial numbers fall The Pharma Letter…
Kodiak's stock doubles as resurrected eye disease drug matches Eylea in phase 3 - Fierce Biotech
Kodiak's stock doubles as resurrected eye disease drug matches Eylea in phase 3 Fierce Biotech…
Expert view: India has an opportunity to become the innovation lab in deep tech - Livemint
Expert view: India has an opportunity to become the innovation lab in deep tech Livemint…
AbbVie's Cerevel buyout delivers as FDA gives go-ahead to 1st-in-class Juvmo in Parkinson's disease - Fierce Pharma
AbbVie's Cerevel buyout delivers as FDA gives go-ahead to 1st-in-class Juvmo in Parkinson's disease Fierce Pharma…
Torrent Pharma raises investment in Torrent Urja 27 to ₹11.88 cr to acquire 26% stake - BusinessLine
Torrent Pharma raises investment in Torrent Urja 27 to ₹11.88 cr to acquire 26% stake BusinessLine…
Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC - BioSpace
Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC BioSpace…
Merck, Daiichi scrap FDA application for B7-H3 ADC in lung cancer - Endpoints News
Merck, Daiichi scrap FDA application for B7-H3 ADC in lung cancer Endpoints News…
Quotient Sciences and Acesion Pharma Announce Collaboration on AI-Enhanced Formulation Development to Advance Atrial Fibrillation Pipeline - bio-itworld.com
Quotient Sciences and Acesion Pharma Announce Collaboration on AI-Enhanced Formulation Development to Advance Atrial Fibrillation Pipeline bio-itworld.com…
Sun Pharma inks global licensing pact with LIB Therapeutics for cholesterol drug Lerodalcibep - BusinessLine
Sun Pharma inks global licensing pact with LIB Therapeutics for cholesterol drug Lerodalcibep BusinessLine…
What’s The Latest On CRISPR Gene Editing Technology? - Forbes
What’s The Latest On CRISPR Gene Editing Technology? Forbes…
Big dreams and tiny revenue are new norm for AI IPOs - Financial Times
Big dreams and tiny revenue are new norm for AI IPOs Financial Times…
Need deeper collaboration between various disciplines for developing targeted drug therapy: Pondicherry University V-C - The Hindu
Need deeper collaboration between various disciplines for developing targeted drug therapy: Pondicherry University V-C The Hindu…
UP's Drug Regulator Tightens Rules On Pharma Discount Practices - News18
UP's Drug Regulator Tightens Rules On Pharma Discount Practices News18…
US FDA approves AbbVie's drug for Parkinson's disease - Reuters
US FDA approves AbbVie's drug for Parkinson's disease Reuters…
Mirum bags FDA approval for ultra-rare bone lesion disorder, heating up rivalry with Regeneron - Fierce Pharma
Mirum bags FDA approval for ultra-rare bone lesion disorder, heating up rivalry with Regeneron Fierce Pharma…
Karnataka may cut drug agents, stockists from hospital supply chain - The Times of India
Karnataka may cut drug agents, stockists from hospital supply chain The Times of India…
Fierce Pharma Asia—Lilly’s $3.35B InnoCare deal; Korea’s breakthrough; China’s 5-year biotech plan - Fierce Pharma
Fierce Pharma Asia—Lilly’s $3.35B InnoCare deal; Korea’s breakthrough; China’s 5-year biotech plan Fierce Pharma…
Lord's Mark Moves AI-Based Radiation-Free Breast Cancer Screening Device Towards Clinical Trials Around... - Moneycontrol.com
Lord's Mark Moves AI-Based Radiation-Free Breast Cancer Screening Device Towards Clinical Trials Around... Moneycontrol.com…
Genentech makes $1.5B+ deal with AI heavyweight Earendil for cancer bispecifics - BioSpace
Genentech makes $1.5B+ deal with AI heavyweight Earendil for cancer bispecifics BioSpace…
Biocon Malaysia gets UK MHRA approval for new drug product fill-finish unit for insulins - BusinessLine
Biocon Malaysia gets UK MHRA approval for new drug product fill-finish unit for insulins BusinessLine…
The Last Mile of Digital Implementation: A Technical Framework for Turning Clinical Technology Adoption Into Measurable Value - Drug Development and Delivery
The Last Mile of Digital Implementation: A Technical Framework for Turning Clinical Technology Adoption Into Measurable Value Drug Development and Delivery…
AI-led drug discovery to create decade-long CDMO tailwind: Harini Dedhia - Business Standard
AI-led drug discovery to create decade-long CDMO tailwind: Harini Dedhia Business Standard…
MedWatch: FDA Safety Information & Adverse Event Reporting Program - fda.gov
MedWatch: FDA Safety Information & Adverse Event Reporting Program fda.gov…